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BACKGROUND: With accumulating knowledge on osteoarthritis development, the next step is to focus on
possibilities for primary prevention.
METHODS: In a 2  2 factorial design, the effects of a diet-and-exercise program and of oral glucosamine
sulfate (double blind and placebo-controlled) on the incidence of knee osteoarthritis were evaluated in a
high-risk group of 407 middle-aged women with a body mass index  27 kg/m2 without clinical signs of
knee osteoarthritis at baseline (ISRCTN 42823086). Primary outcome was the incidence of knee osteo-
arthritis, deﬁned as Kellgren & Lawrence grade  2, joint space narrowing of  1.0 mm, or clinical knee
osteoarthritis (clinical and radiographic American College of Rheumatology criteria) after 2.5 years.
RESULTS: After 2.5 years, only 10% of all subjects were lost to follow-up, and 17% of all knees showed
incident knee osteoarthritis. Accounting for the signiﬁcant interaction between the interventions, no sig-
niﬁcant main effect of either intervention was found. Independently, both interventions alone showed
indications of reduced knee osteoarthritis incidence (odds ratio [OR] 0.69; 95% CI, 0.39-1.21 for the diet-
and-exercise program and OR 0.60; 95% CI, 0.31-1.12 for the glucosamine intervention). These effects
were neutralized in subjects receiving both interventions (OR 0.97; 95% CI, 0.55-1.71).
CONCLUSIONS: No signiﬁcant main effects of the diet-and-exercise program and of glucosamine sulfate
were found on incident knee osteoarthritis. Nevertheless, this trial provides valuable insights for future trial
design for preventive osteoarthritis studies.
 2015 Elsevier Inc. All rights reserved.  The American Journal of Medicine (2015) 128, 888-895
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0.1016/j.amjmed.2015.03.006studies on risk factors for onset of osteoarthritis have been
performed.3,4 These studies have led to the identiﬁcation of a
wide variety of risk factors, mainly focusing on knee osteo-
arthritis. With this accumulated knowledge, primary preven-
tion should be considered.5,6 Several studies indicate that
weight loss in overweight or obese individuals could prevent
knee osteoarthritis.3,7-9 In an observational cohort, it was
calculated that if women with a body mass index (BMI)  25
kg/m2 would reduce their BMI by 2 units (w 5 kg), the risk
for developing knee osteoarthritis would be reduced sub-
stantially (odds ratio [OR] 0.41).8 The direct effects of weight
reduction (primary prevention) on subsequent knee osteoar-
thritis development have never been studied.
Glucosamine has been studied for the treatment of
osteoarthritis patients, but no efﬁcacy has been proven in
Runhaar et al Prevention of Knee Osteoarthritis 889studies with adequate allocation concealment or in
investigator-led studies.10 Literature suggests larger effects
of glucosamine over placebo when used in an early phase
of the disease,11 and especially in the knee joint.12
Glucosamine has never been tested for its preventive ef-
fects. Because all forms of oral glucosamine have beenCLINICAL SIGNIFICANCE
 A pragmatic lifestyle intervention
signiﬁcantly reduced body weight of
middle-aged overweight and obese
women during the ﬁrst year.
 Neither a pragmatic lifestyle interven-
tion aimed to reduce body weight nor an
oral glucosamine sulfate intervention
prevented incident knee osteoarthritis in
middle-aged overweight and obese fe-
males after 30 months.
 Willingness to participate in a preventiveshown to produce no side effects
over placebo, even after long-
term use,13 investigation of the
preventive effect of glucosamine
on incident knee osteoarthritis
seems safe and worthwhile.
The objective of the present
study was to evaluate the effect of
a tailored diet-and-exercise pro-
gram, aimed to reduce weight, and
of oral crystalline glucosamine
sulfate on incidence of knee oste-
oarthritis in a high-risk group of
overweight women between 50
and 60 years of age, free of clin-
ical knee osteoarthritis at baseline.trial is high among middle-aged over-
weight and obese women without knee
symptoms.METHOD
The PROOF study (PRevention of
knee Osteoarthritis in Overweight
Females, ISRCTN 42823086) was
approved by the Medical Ethics Committee of Erasmus
MC University Medical Centre in 2005. The manuscript
has been written according to the CONSORT Statement
guidelines.14 Additional extensive method sections are
provided in the Appendix.Setting and Participants
Women aged 50 to 60 years, with a BMI  27 kg/m2, free
of knee osteoarthritis (clinical American College of
Rheumatology [ACR] criteria15), not treated for knee
complaints or using walking aids, free of magnetic reso-
nance imaging (MRI) contraindications, without rheumatic
diseases, with mastery of the Dutch language, and not
using glucosamine, were recruited through their general
practitioner (Appendix). All women eligible and willing to
participate were invited for baseline measurements (July
2006-May 2009).Physical Examination
At baseline and after 2.5-year follow-up, body weight and
height were measured and both hands were examined for
Heberden nodes.Radiography
Semi-ﬂexed posterior-anterior knee radiographs were
taken at baseline and follow-up according to the meta-
tarsophalangeal protocol16 and scored using the Kellgren& Lawrence (K&L) criteria.17 Minimal joint space width
was measured by visual reading for each tibiofemoral
compartment.18 Medial knee alignment angle was assessed
for all knees19 (Appendix).Questionnaires
At baseline and every 6 months,
participants ﬁlled in questions on
the number of days with knee pain,
activity level (Short QUestionnaire
to ASsess Health-enhancing phys-
ical activity [SQUASH]20), co-
interventions, and quality of life
(EuroQol21). At baseline, 12
months, and 30 months, knee
complaints, Knee injury and Oste-
oarthritis Outcome Score (KOOS)
questionnaire,22 menopausal status,
and comorbidities were addition-
ally assessed.Randomization
After informed consent procedure
according to the declaration of
Helsinki and subsequent baseline
measurements, subjects were ran-domized using consecutive case numbers. For the diet-and-
exercise program, subjects were randomized 1:1 using block
randomization with block size 20. A research assistant not
involved in the trial provided a sealed envelope that was
opened by the subject in the presence of the researcher.
Also, allocation to glucosamine or placebo (double-blind)
was done one-on-one using a blocked randomization list
with block size 20 (see below).Home Visits
Every 6 months, a home visit was planned to measure body
weight, check the questionnaire for missing data, provide
the participant with a new batch of study drugs, and retrieve
the remainder of the previous batch for objective compli-
ance calculation.Diet-and-Exercise Program
A detailed description of the diet-and-exercise program is
given elsewhere.23 In short, subjects in the intervention
group were referred to a local dietician who set goals
regarding nutritional habits and physical activity patterns in
agreement with the participant, using Motivational Inter-
viewing techniques.24 Thereafter, a tailor-made strategy and
an individual plan were composed to achieve these goals.
Additionally, subjects were invited to join a weekly 1-hour
physical exercise class (12-15 participants) for 20 weeks,
supervised by a local physical therapist. A variety of low-
impact sports and exercises, such as Nordic walking, aqua
890 The American Journal of Medicine, Vol 128, No 8, August 2015jogging, and dancing, were offered in order for participants
to regain pleasure in physical activity and ﬁnd activities for
long-term continuation. The control group was not offered
an intervention.Crystalline Glucosamine Sulfate vs Placebo
When designing this trial, high dropout rates in the control
group of the diet-and-exercise program were feared. To
prevent this, the glucosamine sulfate vs placebo intervention
was introduced to provide all subjects with an intervention
and hopefully avoid high dropout rates. Subjects and
research staff were blinded for allocation throughout the
study. All study drugs were provided in identical packaging
by Rottapharm Madaus, who was not involved in study
design, data collection, or statistical analyses. Subjects were
asked to consume one sachet (1500 mg powder) per day for
the total follow-up period.Outcome Measures
Predeﬁned primary outcome was the difference between
groups on the incidence of knee osteoarthritis, deﬁned as
incidence of either K&L  2, clinical knee osteoarthritis
(clinical and radiographic ACR criteria15), or joint space
narrowing of  1.0 mm in the medial or lateral compart-
ment. Secondary outcomes were quality of life, Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) pain and WOMAC function scores (calculated
from KOOS, ranging from 0 to 100, with 0 being no pain/no
functional limitations), weight loss, occurrence of osteoar-
thritis MRI features, and increase in bone and cartilage
degeneration markers. Given the complexity of the MRI and
degeneration marker evaluations, those outcomes will not be
presented here.Sample Size
The study was powered to show an incidence reduction
from 20% in the diet-and-exercise program control group
and in the placebo group to 10% in the diet-and-exercise
program intervention and the glucosamine group
(Appendix). No interaction between the interventions was
assumed. Based on our previous 2-year osteoarthritis
trial,25 we accounted for 10% lost to follow-up. Therefore, 2
groups of 200 subjects would be appropriate (one-sided
testing, alpha ¼ 0.05, beta ¼ 0.80).Statistical Analysis
Intention-to-treat (ITT) analyses on all available data of all
knees of all randomized participants served as primary an-
alyses. The interaction between both interventions was
determined using generalized estimating equations (GEE),
adjusted for confounding variables. Next, the effects of the
diet-and-exercise program and the glucosamine vs placebo
intervention were determined using GEE, adjusted for
confounding variables. In case of a signiﬁcant interactionbetween the interventions, these analyses will be performed
over 4 groups, with subjects in the diet-and-exercise pro-
gram control group receiving placebo as reference
(Appendix).
For the predeﬁned per-protocol (PP) analyses, the ITT
analyses were rerun, between those subjects compliant to
the diet-and-exercise program ( 6 dietary consultations
and  7 exercise classes) and those randomized to the
control group and, separately, in those with an objective
compliance calculation  75%. A sensitivity analysis
excluding all knees fulﬁlling one of the criteria of the pri-
mary outcome at baseline was performed, and all analyses
were repeated on subject level. All analyses were performed
using PASW statistics version 20.0 (SPSS Inc, Chicago, IL).
Available secondary outcomes were analyzed using a
linear mixed model estimated by restricted maximum like-
lihood (SAS 9.2, SAS Institute Inc, Cary, NC). A P-value
< .05 was deﬁned as statistically signiﬁcant for all analyses.
Randomization code for glucosamine vs placebo interven-
tion was broken after all analyses were completed.RESULTS
In total, 6691 women were contacted by 50 general practi-
tioners. Eventually, 407 women were invited for baseline
measurements and were randomized (24.8% to the diet-and-
exercise program intervention/placebo group and 25.1% to
each of the other groups, see Figure). Mean age was 55.7 
3.2 years and mean BMI was 32.4  4.3 kg/m2 (Table 1).
After 2.5 years, 41 women (10.1%) were lost to follow-up.
Of these, 36 women were unwilling; 2 withdrew because of
side effects; one was unattainable; 2 died in the course of the
study. One woman died shortly after the study ended (all
deaths not related to study drugs).
Joint space narrowing (intraclass correlation 0.67-0.76)
was found medially in 5% and laterally in 6% of all knees.
Incidence of K&L grade  2 was found in 4% of all knees
(kappa 0.6). Six percent of all knees showed incident clin-
ical osteoarthritis. Combined into the primary outcome, 135
knees (17%) showed incident knee osteoarthritis (in 28% of
all women). Despite the fact that all included subjects were
free of clinical knee osteoarthritis at initial screening, 3.9%
of all knees fulﬁlled the ACR criteria at baseline and 6.6%
showed K&L grade 2 after detailed assessment of the ra-
diographs. Multivariately, only K&L grade was associated
with the primary outcome.Intention-to-Treat Analyses
The ITT analyses showed a signiﬁcant interaction (P ¼ .04).
Hence, the effects of one intervention depended on the
allocation of the other intervention and 4 groups had to be
analyzed separately (Table 2).Diet-and-Exercise Program
Twenty-eight percent of the 203 women randomized to
the diet-and-exercise program were compliant (equally
Figure Flow-chart of participants in the PRevention of knee Osteoarthritis in
Overweight Females (PROOF) study. DEP ¼ diet-and-exercise program.
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Table 1 Distribution and Mean (SD) of Prognostic Variables Among the Randomized Intervention Arms at Baseline
Diet-and-Exercise Program
Control Group Intervention Group
Placebo Glucosamine Placebo Glucosamine
Subjects, n 102 102 101 102
Age (y) 55.7 (3.3) 55.7 (3.1) 55.7 (3.2) 55.7 (3.1)
BMI, kg/m2 32.6 (4.3) 32.4 (4.6) 32.3 (4.5) 32.1 (3.7)
Heberden nodes
Unilateral 15% 16% 12% 12%
Bilateral 10% 14% 20% 9%
Postmenopausal status 70% 68% 66% 67%
EuroQol, 0-1* 0.90 (0.12) 0.88 (0.13) 0.88 (0.14) 0.90 (0.12)
Physical activity† 6992  3807 7210  3827 6719  3961 6333  3228
WOMAC, 0-100‡
Pain 5.1 (8.5) 7.1 (11.7) 8.1 (13.3) 6.6 (11.4)
Function 5.3 (8.7) 7.1 (12.2) 7.7 (12.2) 5.9 (10.4)
Knees, n 204 204 202 204
K&L
Grade 0 53% 47% 53% 50%
Grade  1 46% 53% 46% 50%
Minimal JSW
Medial, mm 4.4 (0.8) 4.4 (0.8) 4.4 (0.8) 4.4 (0.9)
Lateral, mm 5.9 (1.1) 5.8  0.9 5.8  1.1 6.1 (1.2)
Varus alignment 46% 38% 38% 37%
Mild symptoms 29% 30% 36% 27%
History of knee injury 14% 12% 10% 13%
JSW ¼ joint space width; K&L ¼ Kellgren & Lawrence; WOMAC ¼ Western Ontario and McMaster Universities Osteoarthritis Index.
*Higher scores represent higher quality of life.
†Measured using SQUASH (Short QUestionnaire to ASsess Health-enhancing physical activity).
‡Higher scores represent more pain/worse function.
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Compliant women had a mean weight reduction of 1.4 
5.2 kg at follow-up vs 0.0  6.7 kg in the control group. At
6 and 12 months, the number of participants fulﬁlling the
predeﬁned target of 5 kg or 5% weight reduction was
signiﬁcantly higher in the intervention group (14% vs 6% at
6 months, P ¼ .01; 17% vs 10% at 12 months, P ¼ .04).
Eventually, 63 women (15%) met this target at 30 months.
Detailed effects of the diet-and-exercise program can be
found elsewhere.23
PP analyses showed a signiﬁcant interaction with the
glucosamine vs placebo intervention (P ¼ .01). Incidence ofTable 2 Odds Ratios from Intention-to-treat Analyses for the Four R
Knees n Incident Knee OA
DEP control/placebo 204 19%
DEP control/glucosamine 204 13%
DEP intervention/placebo 202 15%
DEP intervention/glucosamine 204 20%
CI ¼ conﬁdence interval; DEP ¼ diet-and-exercise program; OA ¼ osteoarth
*Unadjusted odds ratio.
†Odds ratio adjusted for baseline Kellgren & Lawrence grade (0 vs  1).knee osteoarthritis was found in 19%, 13%, 9%, and 23% of
the knees of subjects randomized to the control group with
placebo, with glucosamine, subjects compliant to the diet-
and-exercise program with placebo, and those with glucos-
amine, respectively (Table 3).Oral Glucosamine Sulfate vs Placebo
A total of 291 adverse events were reported by a total of 118
women, equally divided between the glucosamine and pla-
cebo groups (chi-squared test: P ¼ .23). All reported serious
adverse events (26 by 25 women) were classiﬁed as notandomized Groups on Incidence of Knee OA
OR* 95% CI OR† 95% CI
1 (Reference) 1 (Reference)
0.610 0.328-1.135 0.591 0.313-1.118
0.695 0.396-1.213 0.685 0.389-1.208
1.010 0.579-1.763 0.972 0.553-1.710
ritis; OR ¼ odds ratio.
Table 3 Odds Ratios from Per-protocol Analyses on Incidence of Knee OA
Knees n Incident Knee OA OR* 95% CI OR† 95% CI
DEP control/placebo 204 19% 1 (Reference) 1 (Reference)
DEP control/glucosamine 204 13% 0.610 0.328-1.135 0.590 0.310-1.122
Compliant to DEP/placebo 58 9% 0.341 0.109-1.063 0.349 0.110-1.105
Compliant to DEP/glucosamine 56 23% 1.220 0.567-2.628 1.277 0.594-2.747
CI ¼ conﬁdence interval; DEP ¼ diet-and-exercise program; OA ¼ osteoarthritis; OR ¼ odds ratio.
*Unadjusted odds ratio.
†Odds ratio adjusted for baseline Kellgren & Lawrence grade (0 vs  1).
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groups (chi-squared test: P ¼ .26). After study ending, 17%
of the women in the placebo group and 15% of the women
in the glucosamine group were convinced they had received
glucosamine. The majority of all women (52% in the pla-
cebo group and 46% in the glucosamine group) were
convinced they received placebo (chi-squared test: P ¼ .24).
None of the involved researchers or participants were un-
blinded during the trial. In total, 250 women were compliant
(66% of the placebo group, 57% of the glucosamine group).
PP analyses showed no interaction between both in-
terventions (P ¼ .17). Incidence of knee osteoarthritis
occurred in 20% of the knees of the women compliant to the
placebo (21% in the control group and 18% in the diet-and-
exercise program intervention group), and in 21% (17% in
control group and 24% in the diet-and-exercise program
intervention group) of the knees of women compliant to
glucosamine (adjusted OR 0.99 [95% CI, 0.61-1.63]).Secondary Outcome
Secondary outcomes are represented in Appendix
Figures 1-4 (available online). There was a statistically
signiﬁcant difference only between the diet-and-exercise
program intervention and control group on actual weight
loss (P ¼ .04). Detailed analyses showed a signiﬁcant dif-
ference in weight loss at 6 months (P < .01) and 12 months
(P ¼ .01). Also in PP analyses, only the effect of the diet-
and-exercise program on actual weight loss was statisti-
cally signiﬁcant in favor of the intervention group (P ¼ .01),
with statistically signiﬁcant differences in weight loss at 6
months (P < .01), 12 months (P < .01), 18 months (P ¼
.02), and 24 months (P ¼ .04).Sensitivity Analysis
When excluding all knees fulﬁlling one of the items of the
primary outcome at baseline, the interaction between both
interventions was borderline signiﬁcant in the ITT analyses
(P ¼ .10) and statistically signiﬁcant in the PP analysis for
the diet-and-exercise program (P ¼ .03) (Appendix
Tables 1 and 2, available online). In the sensitivity
analyses at subject level, the interaction between both
interventions was also borderline signiﬁcant in ITT
analyses (P ¼ .12) and statistically signiﬁcant in PPanalyses for the diet-and-exercise program (P < .01)
(Appendix Tables 3 and 4, available online).DISCUSSION
This study presents the ﬁrst-ever preventive randomized trial
on osteoarthritis worldwide. The diet-and-exercise program
and the glucosamine sulfate intervention showed no sig-
niﬁcant main effects on the incidence of knee osteoarthritis
after 2.5 years. However, due to the unexpected signiﬁcant
interaction, these analyses were slightly underpowered. The
fact that the interaction became even stronger in subjects
compliant to the diet-and-exercise program was found in
sensitivity analyses, and at subject level, indicates a true
interaction between the interventions.
This preventive randomized trial focused on subjects
with high risk of developing knee osteoarthritis and used a
combined outcome measure to make a trial in such a slowly
progressing disease feasible over a relative short time
period. This combination of radiographic and clinical mea-
sures of knee osteoarthritis into the primary outcome im-
proves the ability to determine the preventive effects of the
studied interventions,5 although one misses the detailed
insight in the development of the disease. Explorative
evaluation of the separate items of the primary outcome
conﬁrmed the pattern found in the main analyses, but longer
follow-up is needed to statistically test these outcomes
separately given the naturally slow disease development.
Although we found no signiﬁcant main effects of the diet-
and-exercise program and the glucosamine vs placebo inter-
vention on primary outcomes, the interaction between the
interventions did show several interesting results. Where
glucosamine sulfate reduced osteoarthritis incidence numbers
in the group not undergoing the diet-and-exercise program
(13% vs 19%; adjusted OR 0.59 [95% CI, 0.31-1.12]), oste-
oarthritis incidence was increased in the glucosamine sulfate
group within the diet-and-exercise program intervention
group (20% vs 15%; adjusted OR 1.44 [95% CI, 0.83-2.48]).
On the other hand, the diet-and-exercise program reduced the
incidence numbers within the placebo group (15% vs 19%;
adjusted OR 0.69 [95% CI, 0.39-1.21]), but showed an
increased OR within the glucosamine sulfate group (20% vs.
13%; adjusted OR 1.63 [95% CI, 0.89-3.01]). Taking only
subjects compliant with the diet-and-exercise program into
account, the effects became even stronger (9% vs. 19%;
894 The American Journal of Medicine, Vol 128, No 8, August 2015adjusted OR 0.35 [95% CI, 0.11-1.10] within the placebo
group and 23% vs 13%; adjusted OR 2.17 [95% CI, 0.95-
4.96] within the glucosamine sulfate group). Although
tested in subjects with established knee osteoarthritis,
results from Messier et al26 might give some suggestion
for the mechanism behind this interaction. Messier and
co-workers found that after a 6-month exercise period,
subjects randomized to a combination of glucosamine/
chondroitin decreased in knee ﬂexion strength, whereas
subjects receiving placebo signiﬁcantly improved their
strength.26 These results suggest that glucosamine might
interfere with processes of repair and growth after physical
exercise. On the other hand, a 12-week training program
combined with glucosamine sulfate did not show a dif-
ference in knee extension strength over the placebo group
in knee osteoarthritis patients.27 The more sensitive and
explorative measures of the MRI and biomarkers, which
are being assessed within the present study, might provide
more detailed information on the underlying mechanism.
For implementation reasons, a very pragmatic design was
chosen for the diet-and-exercise program. Nevertheless, the
intervention had a signiﬁcant effect on the actual weight loss
during the ﬁrst year of follow-up, and activity levels were
higher in the intervention group throughout the total follow-
up period. Thus, despite the relatively low compliance ﬁg-
ures, similar to other physical exercise and diet interventions
in overweight and obese individuals,28 and a short duration,
the current diet-and-exercise program succeeded in a low-
level change in lifestyle, also in the ITT population. Con-
trary to daily practice, the control group was relatively
active. Nearly 90% of all subjects reported a preference for
the intervention group at baseline. For ethical reasons, the
control group was not actively refrained from any in-
terventions on weight loss. After 2.5 years, 18% of all
women randomized to the control group fulﬁlled the crite-
rion of losing 5 kg or 5% of baseline body weight. There-
fore, the effects of the diet-and-exercise program found on
incident knee osteoarthritis may have been underestimated.
In conclusion, we showed no signiﬁcant main effects of
the diet-and-exercise program or the glucosamine vs pla-
cebo intervention on incidence of knee osteoarthritis over
2.5 years. These analyses, however, were hampered by an
unexpected signiﬁcant interaction between the 2 in-
terventions. The current trial provides many new insights in
the possibilities for prevention of knee osteoarthritis within
a high-risk group of middle-aged, overweight women. The
low dropout rate of 10% strengthens results of this ﬁrst
attempt to prevent osteoarthritis in subjects at high risk. The
indications for preventive effects of the 2 interventions
separately and their interaction needs further elaboration.
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ADDITIONAL METHOD SECTION
Setting and Participants
Fifty general practitioners in the region of Rotterdam, The
Netherlands, sent study information and a reply card to all
registered women between 50 and 60 years of age without
major comorbidities. Interested women with a reported body
mass index (BMI)  27 kg/m2 were contacted by phone to
check all inclusion criteria. Besides age and BMI-related
inclusion criteria, subjects had to be free of knee osteoar-
thritis according to the clinical American College of Rheu-
matology (ACR) criteria,1 not under treatment for knee
complaints, free of magnetic resonance imaging contrain-
dications, free of rheumatic diseases, not using walking aids,
have mastery of the Dutch language, and not using oral
glucosamine for the last 6 months.
Radiography
Semi-ﬂexed posterior-anterior knee radiographs were
taken at baseline and follow-up according to the meta-
tarsophalangeal protocol.2 A trained researcher (MR), blin-
ded for clinical outcomes and treatment assignment, scored
all radiographs (baseline and follow-up images at once with
known sequence) using the Kellgren & Lawrence (K&L)
criteria.3 A random subset of 20% of the radiographs was
scored by a second blinded researcher (JR) to determine
interobserver variability. Minimal joint space width was
measured by visual reading with the use of a digital ruler for
each tibiofemoral compartment4 using the average score of 2
researchers blinded for clinical outcomes and baseline mea-
surements (JR and BdV). Scores with a difference between
both readers 2.0 mm were re-evaluated during a consensus
meeting. Medial knee alignment angle was assessed by
digitally determining the angle between the line from the
center of the tibial spines through the center of the femoral
shaft at approximately 10 cm from the joint margin and the
matching line through the tibia.5
Sample Size
The study was powered to show an incidence reduction
from 20% in the diet-and-exercise program control group
and in the placebo group to 10% in the diet-and-exercise
program intervention and the glucosamine group. These
numbers were based on a 12-year follow-up study with an
overall incidence of K&L  2 of 39.1% in subjects with a
BMI  26.4 kg/m2.6 In the present age group, this number
was 1.6-fold higher, suggesting an incidence of 13% over
2.5 years. The primary outcome combined incidence of
K&L grade  2, ACR criteria, and joint space narrowing.Because there is only moderate overlap between these
measures,7 a 20% incidence in the control group seemed
reasonable. No interaction between the interventions was
assumed. Based on rates in our previous 2-year osteoar-
thritis trial,8 we accounted for 10% lost to follow-up.
Therefore, 2 groups of 200 subjects would be appropriate
(one-sided testing, alpha ¼ 0.05, beta ¼ 0.80).Statistical Analysis
Intention-to-treat (ITT) analyses on all available data of all
knees of all randomized participants served as primary an-
alyses. First, the univariate association between known
prognostic variables (age, K&L grade 1 vs 0), varus
alignment (< 178 vs  178),9 mild knee symptoms (“Did
you experience knee pain in the past 12 months?”), BMI, a
history of knee injury, Heberden nodes, and postmenopausal
status; and the primary outcome was determined using
generalized estimating equations (GEE), with the associa-
tion between 2 knees within one person taken into account.
Variables with a P-value < .2 were analyzed multivariately.
Variables with a P-value < .05 in the multivariate model
were adopted as confounders. Second, the interaction be-
tween both interventions was determined using GEE,
adjusted for the confounding variables. Third, the effects of
diet-and-exercise program and the glucosamine vs placebo
intervention were determined using GEE, adjusted for the
confounding variables. In case of a signiﬁcant interaction
between the interventions, these analyses will be performed
over 4 groups, with subjects in the diet-and-exercise pro-
gram control group receiving placebo as the reference
group.
For the predeﬁned per-protocol (PP) analyses, the latter 2
ITT analyses were rerun between those subjects compliant
to the diet-and-exercise program ( 6 dietary consultations
and  7 attended physical exercise classes) and those ran-
domized to the control group and, separately, in those with
an objective compliance calculation  75% of the study
drug throughout the study period. A sensitivity analysis
excluding all knees fulﬁlling one of the criteria of the pri-
mary outcome at baseline was performed, and ﬁnally, all
analyses were repeated on a subject level. All analyses were
performed using PASW statistics version 20.0 (SPSS Inc,
Chicago, IL).
Available secondary outcomes were analyzed using a
linear mixed model estimated by restricted maximum like-
lihood to test effects of both interventions and their inter-
action over the follow-up period (SAS 9.2, SAS Institute
Inc, Cary, NC). A P-value < .05 was deﬁned as statistically
signiﬁcant for all analyses. Randomization code for
glucosamine vs placebo intervention was broken after all
analyses were completed.
Appendix Figure 3 Mean WOMAC function scores (range
0-100; higher scores mean less function) within randomized
intervention groups.
Appendix Figure 1 Mean quality of life (EuroQol) scores
within randomized intervention groups.
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0-100; higher scores mean more pain) within randomized
intervention groups.
Appendix Figure 4 Actual weight loss (negative values
represent weight gain from baseline) within randomized
intervention groups.
Appendix Table 1 Odds Ratios from Sensitivity Analyses (Intention To Treat), Excluding Knees Already Fulﬁlling One of the Criteria of
the Primary Outcome on Baseline
Knees n Incident Knee OA OR* 95% CI OR† 95% CI
DEP control/placebo 186 16% 1 (Reference) 1 (Reference)
DEP control/glucosamine 186 12% 0.73 0.37-1.45 0.72 0.36-1.44
DEP intervention/placebo 179 13% 0.71 0.38-1.35 0.71 0.37-1.36
DEP intervention/glucosamine 179 18% 1.15 0.61-2.17 1.12 0.59-2.14
CI ¼ conﬁdence interval; DEP ¼ diet-and-exercise program; OA ¼ osteoarthritis; OR ¼ odds ratio.
*Unadjusted odds ratio.
†Odds ratio adjusted for baseline Kellgren & Lawrence grade (0 vs  1).
Appendix Table 2 Odds Ratios from Sensitivity Analyses (Per Protocol for DEP), Excluding Knees Already Fulﬁlling One of the Criteria of
the Primary Outcome on Baseline
Knees n Incident Knee OA OR* 95% CI OR† 95% CI
DEP control/placebo 186 16% 1 (Reference) 1 (Reference)
DEP control/glucosamine 186 12% 0.73 0.37-1.45 0.71 0.35-1.45
DEP intervention/placebo 56 9% 0.45 0.14-1.43 0.45 0.14-1.46
DEP intervention/glucosamine 48 23% 1.52 0.68-3.41 1.63 0.72-3.65
CI ¼ conﬁdence interval; DE ¼ diet-and-exercise program; OA ¼ osteoarthritis; OR ¼ odds ratio.
*Unadjusted odds ratio.
†Odds ratio adjusted for baseline Kellgren & Lawrence grade (0 vs  1).
Appendix Table 4 Odds Ratios from Sensitivity Analyses (Per Protocol for DEP) at Subject Level
n Incident Knee OA* OR† 95% CI OR‡ 95% CI
DEP control/placebo 102 29% 1 (Reference) 1 (Reference)
DEP control/glucosamine 102 21% 0.58 0.30-1.13 0.65 0.32-1.30
DEP intervention/placebo 29 14% 0.31 0.10-0.96 0.31 0.09-1.06
DEP intervention/glucosamine 28 39% 1.44 0.58-3.57 2.21 0.77-6.28
CI ¼ conﬁdence interval; DEP ¼ diet-and-exercise program; OA ¼ osteoarthritis; OR ¼ odds ratio.
*Deﬁned as primary outcome in one or both knees.
†Unadjusted odds ratio.
‡Odds ratio adjusted for baseline Kellgren & Lawrence grade, varus alignment, and mild symptoms all deﬁned as in 0 vs  1 knee, and baseline BMI.
Appendix Table 3 Odds Ratios from Sensitivity Analyses (Intention To Treat) at Subject Level
n Incident Knee OA* OR† 95% CI OR‡ 95% CI
DEP control/placebo 102 29% 1 (Reference) 1 (Reference)
DEP control/glucosamine 102 21% 0.58 0.30-1.13 0.64 0.32-1.26
DEP intervention/placebo 101 28% 0.83 0.44-1.56 0.89 0.46-1.72
DEP intervention/glucosamine 102 32% 1.04 0.56-1.93 1.20 0.63-230
CI ¼ conﬁdence interval; DEP ¼ diet-and-exercise program; OA ¼ osteoarthritis; OR ¼ odds ratio.
*Deﬁned as primary outcome in one or both knees.
†Unadjusted odds ratio.
‡Odds ratio adjusted for baseline Kellgren & Lawrence grade, varus alignment, and mild symptoms all deﬁned as in 0 vs  1 knee, and baseline body
mass index.
895.e3 The American Journal of Medicine, Vol 128, No 8, August 2015
References
1. Altman R, Asch E, Bloch D, et al. Development of criteria for the
classiﬁcation and reporting of osteoarthritis. Arthritis Rheum.
1986;29(8):1039-1049.
2. Buckland-Wright JC, Wolfe F, Ward RJ, et al. Substantial superiority
of semiﬂexed (MTP) views in knee osteoarthritis: a comparative
radiographic study, without ﬂuoroscopy, of standing extended,
semiﬂexed (MTP), and schuss views. J Rheumatol. 1999;26(12):
2664-2674.
3. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis.
Ann Rheum Dis. 1957;16(4):494-502.
4. Lequesne M. Quantitative measurements of joint space during pro-
gression of osteoarthritis: chondrometry. In: Kuettner K, Goldberg V,
eds. Osteoarthritic Disorders. Rosemont, IL: American Academy of
Orthopaedic Surgeons; 1995:427-444.
5. Kraus VB, Vail TP, Worrell T, McDaniel G. A comparative assessment
of alignment angle of the knee by radiographic and physical examination
methods. Arthritis Rheum. 2005;52(6):1730-1735.
6. Schouten JSAG. A Twelve Year Follow-up Study on Osteoarthritis of the
Knee in the General Population. Rotterdam, the Netherlands: Erasmus
University Rotterdam; 1991.
7. Peat G, Thomas E, Duncan R, et al. Clinical classiﬁcation criteria for
knee osteoarthritis: performance in the general population and primary
care. Ann Rheum Dis. 2006;65(10):1363-1367.
8. Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine
sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med.
2008;148(4):268-277.
9. Brouwer GM, van Tol AW, Bergink AP, et al. Association between
valgus and varus alignment and the development and progression of
radiographic osteoarthritis of the knee. Arthritis Rheum. 2007;56(4):
1204-1211.
Runhaar et al Prevention of Knee Osteoarthritis 895.e4
